These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 24445497)

  • 1. Endoglin for targeted cancer treatment.
    Rosen LS; Gordon MS; Robert F; Matei DE
    Curr Oncol Rep; 2014 Feb; 16(2):365. PubMed ID: 24445497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer.
    Gordon MS; Robert F; Matei D; Mendelson DS; Goldman JW; Chiorean EG; Strother RM; Seon BK; Figg WD; Peer CJ; Alvarez D; Adams BJ; Theuer CP; Rosen LS
    Clin Cancer Res; 2014 Dec; 20(23):5918-26. PubMed ID: 25261556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer.
    Liu Y; Starr MD; Brady JC; Dellinger A; Pang H; Adams B; Theuer CP; Lee NY; Hurwitz HI; Nixon AB
    Cancer Med; 2014 Jun; 3(3):580-91. PubMed ID: 24574330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer.
    Dorff TB; Longmate JA; Pal SK; Stadler WM; Fishman MN; Vaishampayan UN; Rao A; Pinksi JK; Hu JS; Quinn DI; Lara PN
    Cancer; 2017 Dec; 123(23):4566-4573. PubMed ID: 28832978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer.
    Karzai FH; Apolo AB; Cao L; Madan RA; Adelberg DE; Parnes H; McLeod DG; Harold N; Peer C; Yu Y; Tomita Y; Lee MJ; Lee S; Trepel JB; Gulley JL; Figg WD; Dahut WL
    BJU Int; 2015 Oct; 116(4):546-55. PubMed ID: 25407442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer.
    Rosen LS; Hurwitz HI; Wong MK; Goldman J; Mendelson DS; Figg WD; Spencer S; Adams BJ; Alvarez D; Seon BK; Theuer CP; Leigh BR; Gordon MS
    Clin Cancer Res; 2012 Sep; 18(17):4820-9. PubMed ID: 22767667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma.
    Choueiri TK; Michaelson MD; Posadas EM; Sonpavde GP; McDermott DF; Nixon AB; Liu Y; Yuan Z; Seon BK; Walsh M; Jivani MA; Adams BJ; Theuer CP
    Oncologist; 2019 Feb; 24(2):202-210. PubMed ID: 30190302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer.
    Paauwe M; Heijkants RC; Oudt CH; van Pelt GW; Cui C; Theuer CP; Hardwick JC; Sier CF; Hawinkels LJ
    Oncogene; 2016 Aug; 35(31):4069-79. PubMed ID: 26804178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Facilitation of endoglin-targeting cancer therapy by development/utilization of a novel genetically engineered mouse model expressing humanized endoglin (CD105).
    Toi H; Tsujie M; Haruta Y; Fujita K; Duzen J; Seon BK
    Int J Cancer; 2015 Jan; 136(2):452-61. PubMed ID: 24866768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105.
    Liu Y; Starr MD; Brady JC; Rushing C; Pang H; Adams B; Alvarez D; Theuer CP; Hurwitz HI; Nixon AB
    Mol Cancer Ther; 2018 Oct; 17(10):2248-2256. PubMed ID: 29997150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the combination of TRC105 and bevacizumab on endothelial cell biology.
    Liu Y; Tian H; Blobe GC; Theuer CP; Hurwitz HI; Nixon AB
    Invest New Drugs; 2014 Oct; 32(5):851-9. PubMed ID: 24994097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-β signaling.
    Kumar S; Pan CC; Bloodworth JC; Nixon AB; Theuer C; Hoyt DG; Lee NY
    Oncogene; 2014 Jul; 33(30):3970-9. PubMed ID: 24077288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endoglin for tumor imaging and targeted cancer therapy.
    Paauwe M; ten Dijke P; Hawinkels LJ
    Expert Opin Ther Targets; 2013 Apr; 17(4):421-35. PubMed ID: 23327677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
    Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
    Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of antiangiogenesis therapy: bevacizumab and beyond.
    Cortés-Funes H
    Clin Transl Oncol; 2009 Jun; 11(6):349-55. PubMed ID: 19531449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma.
    Guillot A; Levy A; Pacaut C; Collard O; Massard C; Merrouche Y; Magné N
    Clin Genitourin Cancer; 2012 Sep; 10(3):147-52. PubMed ID: 22796529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
    Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C
    Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.